---
document_datetime: 2025-11-23 08:01:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/naveruclif.html
document_name: naveruclif.html
version: success
processing_time: 0.1074677
conversion_datetime: 2025-12-27 14:45:17.32322
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Naveruclif

[RSS](/en/individual-human-medicine.xml/89042)

##### Authorised

This medicine is authorised for use in the European Union

paclitaxel

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Naveruclif](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Naveruclif is used to treat the following cancers in adults:

- metastatic breast cancer, when the first treatment has stopped working and standard treatment including an anthracycline (another type of cancer medicine) is not suitable. 'Metastatic' means that the cancer has spread to other parts of the body;
- metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine;
- non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin, when the patient cannot have surgery or radiotherapy.

Naveruclif is a 'generic medicine'. This means that Naveruclif contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Naveruclif is Abraxane. For more information on generic medicines, see the question-and-answer document here.

Naveruclif contains the active substance paclitaxel attached to a human protein called albumin.

Expand section

Collapse section

## How is Naveruclif used?

Naveruclif can only be obtained with a prescription and should only be given under the supervision of a specialist cancer doctor in units that are specialised in giving 'cytotoxic' (cell-killing) medicines. It should not be interchanged with other medicines containing paclitaxel.

Naveruclif is given as an infusion into a vein over a period of 30 minutes. The recommended dose depends on the patient's height and weight and on the condition the patient is treated for.

In metastatic breast cancer, Naveruclif is given on its own every three weeks.

In metastatic adenocarcinoma of the pancreas, Naveruclif is given in 4-week treatment cycles. The medicine is given once a day on days 1, 8 and 15 of each cycle. Immediately after giving Naveruclif, gemcitabine should be given.

In non-small cell lung cancer, treatment is carried out in 3-week cycles with Naveruclif given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Naveruclif.

For more information about using Naveruclif, see the package leaflet or contact your doctor or pharmacist.

## How does Naveruclif work?

The active substance in Naveruclif, paclitaxel, blocks a stage of cell division in which the cell's internal 'skeleton' is dismantled to allow the cell to divide. By keeping this structure intact, the cells cannot divide and they eventually die. Naveruclif also affects non-cancer cells such as blood and nerve cells, which can cause side effects.

Paclitaxel has been available as a cancer medicine since 1993. In Naveruclif, as in its reference medicine Abraxane, paclitaxel is attached to a human protein called albumin in tiny particles known as 'nanoparticles'. This makes it easy to prepare a suspension of paclitaxel, which can be infused into a vein.

## How has Naveruclif been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Abraxane, and do not need to be repeated for Naveruclif.

As for every medicine, the company provided studies on the quality of Naveruclif. There was no need for 'bioequivalence' studies to investigate whether Naveruclif is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Naveruclif is given by infusion into a vein and the nanoparticles it contains rapidly separate into its constituent parts in the same way as Abraxane's.

## What are the benefits and risks of Naveruclif?

Because Naveruclif is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Naveruclif authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Naveruclif has been shown to be comparable to Abraxane. Therefore, the Agency's view was that, as for Abraxane, the benefits of Naveruclif outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Naveruclif?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Naveruclif have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Naveruclif are continuously monitored. Suspected side effects reported with Naveruclif are carefully evaluated and any necessary action taken to protect patients.

## Other information about Naveruclif

Naveruclif received a marketing authorisation valid throughout the EU on 5 January 2024.

This overview was last updated in 01-2024.

Naveruclif : EPAR - Medicine Overview

Reference Number: EMEA/H/C/006173

English (EN) (166.62 KB - PDF)

**First published:** 27/02/2024

[View](/en/documents/overview/naveruclif-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-682)

български (BG) (182.08 KB - PDF)

**First published:**

27/02/2024

[View](/bg/documents/overview/naveruclif-epar-medicine-overview_bg.pdf)

español (ES) (167.53 KB - PDF)

**First published:**

27/02/2024

[View](/es/documents/overview/naveruclif-epar-medicine-overview_es.pdf)

čeština (CS) (188.12 KB - PDF)

**First published:**

27/02/2024

[View](/cs/documents/overview/naveruclif-epar-medicine-overview_cs.pdf)

dansk (DA) (165.94 KB - PDF)

**First published:**

27/02/2024

[View](/da/documents/overview/naveruclif-epar-medicine-overview_da.pdf)

Deutsch (DE) (170.15 KB - PDF)

**First published:**

27/02/2024

[View](/de/documents/overview/naveruclif-epar-medicine-overview_de.pdf)

eesti keel (ET) (164.57 KB - PDF)

**First published:**

27/02/2024

[View](/et/documents/overview/naveruclif-epar-medicine-overview_et.pdf)

ελληνικά (EL) (189.3 KB - PDF)

**First published:**

27/02/2024

[View](/el/documents/overview/naveruclif-epar-medicine-overview_el.pdf)

français (FR) (168.05 KB - PDF)

**First published:**

27/02/2024

[View](/fr/documents/overview/naveruclif-epar-medicine-overview_fr.pdf)

hrvatski (HR) (187.41 KB - PDF)

**First published:**

27/02/2024

[View](/hr/documents/overview/naveruclif-epar-medicine-overview_hr.pdf)

italiano (IT) (166.22 KB - PDF)

**First published:**

27/02/2024

[View](/it/documents/overview/naveruclif-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (196.54 KB - PDF)

**First published:**

27/02/2024

[View](/lv/documents/overview/naveruclif-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (188.92 KB - PDF)

**First published:**

27/02/2024

[View](/lt/documents/overview/naveruclif-epar-medicine-overview_lt.pdf)

magyar (HU) (188.77 KB - PDF)

**First published:**

27/02/2024

[View](/hu/documents/overview/naveruclif-epar-medicine-overview_hu.pdf)

Malti (MT) (190.03 KB - PDF)

**First published:**

27/02/2024

[View](/mt/documents/overview/naveruclif-epar-medicine-overview_mt.pdf)

Nederlands (NL) (167.3 KB - PDF)

**First published:**

27/02/2024

[View](/nl/documents/overview/naveruclif-epar-medicine-overview_nl.pdf)

polski (PL) (191.63 KB - PDF)

**First published:**

27/02/2024

[View](/pl/documents/overview/naveruclif-epar-medicine-overview_pl.pdf)

português (PT) (167.68 KB - PDF)

**First published:**

27/02/2024

[View](/pt/documents/overview/naveruclif-epar-medicine-overview_pt.pdf)

română (RO) (186.34 KB - PDF)

**First published:**

27/02/2024

[View](/ro/documents/overview/naveruclif-epar-medicine-overview_ro.pdf)

slovenčina (SK) (188.39 KB - PDF)

**First published:**

27/02/2024

[View](/sk/documents/overview/naveruclif-epar-medicine-overview_sk.pdf)

slovenščina (SL) (185.53 KB - PDF)

**First published:**

27/02/2024

[View](/sl/documents/overview/naveruclif-epar-medicine-overview_sl.pdf)

Suomi (FI) (165.1 KB - PDF)

**First published:**

27/02/2024

[View](/fi/documents/overview/naveruclif-epar-medicine-overview_fi.pdf)

svenska (SV) (165.51 KB - PDF)

**First published:**

27/02/2024

[View](/sv/documents/overview/naveruclif-epar-medicine-overview_sv.pdf)

Naveruclif : EPAR - Risk-management-plan summary

English (EN) (625.33 KB - PDF)

**First published:** 27/02/2024

[View](/en/documents/rmp-summary/naveruclif-epar-risk-management-plan-summary_en.pdf)

## Product information

Naveruclif : EPAR - Product Information

English (EN) (438.59 KB - PDF)

**First published:** 27/02/2024

**Last updated:** 12/08/2025

[View](/en/documents/product-information/naveruclif-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-364)

български (BG) (695.22 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/bg/documents/product-information/naveruclif-epar-product-information_bg.pdf)

español (ES) (539.29 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/es/documents/product-information/naveruclif-epar-product-information_es.pdf)

čeština (CS) (622.92 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/cs/documents/product-information/naveruclif-epar-product-information_cs.pdf)

dansk (DA) (391.23 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/da/documents/product-information/naveruclif-epar-product-information_da.pdf)

Deutsch (DE) (439.94 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/de/documents/product-information/naveruclif-epar-product-information_de.pdf)

eesti keel (ET) (873.39 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/et/documents/product-information/naveruclif-epar-product-information_et.pdf)

ελληνικά (EL) (497.5 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/el/documents/product-information/naveruclif-epar-product-information_el.pdf)

français (FR) (693.99 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/fr/documents/product-information/naveruclif-epar-product-information_fr.pdf)

hrvatski (HR) (430.47 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/hr/documents/product-information/naveruclif-epar-product-information_hr.pdf)

íslenska (IS) (392.28 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/is/documents/product-information/naveruclif-epar-product-information_is.pdf)

italiano (IT) (407.53 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/it/documents/product-information/naveruclif-epar-product-information_it.pdf)

latviešu valoda (LV) (453.9 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/lv/documents/product-information/naveruclif-epar-product-information_lv.pdf)

lietuvių kalba (LT) (975.4 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/lt/documents/product-information/naveruclif-epar-product-information_lt.pdf)

magyar (HU) (658.59 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/hu/documents/product-information/naveruclif-epar-product-information_hu.pdf)

Malti (MT) (498.79 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/mt/documents/product-information/naveruclif-epar-product-information_mt.pdf)

Nederlands (NL) (430.51 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/nl/documents/product-information/naveruclif-epar-product-information_nl.pdf)

norsk (NO) (378.96 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/no/documents/product-information/naveruclif-epar-product-information_no.pdf)

polski (PL) (601.26 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/pl/documents/product-information/naveruclif-epar-product-information_pl.pdf)

português (PT) (436.43 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/pt/documents/product-information/naveruclif-epar-product-information_pt.pdf)

română (RO) (440.24 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/ro/documents/product-information/naveruclif-epar-product-information_ro.pdf)

slovenčina (SK) (422.27 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/sk/documents/product-information/naveruclif-epar-product-information_sk.pdf)

slovenščina (SL) (454.65 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/sl/documents/product-information/naveruclif-epar-product-information_sl.pdf)

Suomi (FI) (631.07 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/fi/documents/product-information/naveruclif-epar-product-information_fi.pdf)

svenska (SV) (411.44 KB - PDF)

**First published:**

27/02/2024

**Last updated:**

12/08/2025

[View](/sv/documents/product-information/naveruclif-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000287045 11/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Naveruclif : EPAR - All Authorised Presentations

Reference Number: EMA/513688/2023

English (EN) (159.09 KB - PDF)

**First published:** 27/02/2024

[View](/en/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-784)

български (BG) (67.23 KB - PDF)

**First published:**

27/02/2024

[View](/bg/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.3 KB - PDF)

**First published:**

27/02/2024

[View](/es/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_es.pdf)

čeština (CS) (63.29 KB - PDF)

**First published:**

27/02/2024

[View](/cs/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.93 KB - PDF)

**First published:**

27/02/2024

[View](/da/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (26.16 KB - PDF)

**First published:**

27/02/2024

[View](/de/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (25.86 KB - PDF)

**First published:**

27/02/2024

[View](/et/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (64.67 KB - PDF)

**First published:**

27/02/2024

[View](/el/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_el.pdf)

français (FR) (26.05 KB - PDF)

**First published:**

27/02/2024

[View](/fr/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.56 KB - PDF)

**First published:**

27/02/2024

[View](/hr/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (25.78 KB - PDF)

**First published:**

27/02/2024

[View](/is/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_is.pdf)

italiano (IT) (26.08 KB - PDF)

**First published:**

27/02/2024

[View](/it/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.84 KB - PDF)

**First published:**

27/02/2024

[View](/lv/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (62.78 KB - PDF)

**First published:**

27/02/2024

[View](/lt/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (46.46 KB - PDF)

**First published:**

27/02/2024

[View](/hu/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.65 KB - PDF)

**First published:**

27/02/2024

[View](/mt/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (26.08 KB - PDF)

**First published:**

27/02/2024

[View](/nl/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.03 KB - PDF)

**First published:**

27/02/2024

[View](/no/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_no.pdf)

polski (PL) (63.88 KB - PDF)

**First published:**

27/02/2024

[View](/pl/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.17 KB - PDF)

**First published:**

27/02/2024

[View](/pt/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_pt.pdf)

română (RO) (62.54 KB - PDF)

**First published:**

27/02/2024

[View](/ro/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (63.41 KB - PDF)

**First published:**

27/02/2024

[View](/sk/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.46 KB - PDF)

**First published:**

27/02/2024

[View](/sl/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.85 KB - PDF)

**First published:**

27/02/2024

[View](/fi/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.06 KB - PDF)

**First published:**

27/02/2024

[View](/sv/documents/all-authorised-presentations/naveruclif-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Naveruclif Active substance paclitaxel International non-proprietary name (INN) or common name paclitaxel Therapeutic area (MeSH)

- Breast Neoplasms
- Pancreatic Neoplasms
- Carcinoma, Non-Small-Cell Lung

Anatomical therapeutic chemical (ATC) code L01CD01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Naveruclif monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated (see section 4.4).

Naveruclif in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

Naveruclif in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

## Authorisation details

EMA product number EMEA/H/C/006173

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 09/11/2023 Marketing authorisation issued 05/01/2024 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Naveruclif : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (158.77 KB - PDF)

**First published:** 01/07/2025

**Last updated:** 12/08/2025

[View](/en/documents/procedural-steps-after/naveruclif-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Naveruclif : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (304.9 KB - PDF)

**First published:** 13/03/2025

**Last updated:** 01/07/2025

[View](/en/documents/procedural-steps-after/naveruclif-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Naveruclif : EPAR - Public Assessment Report

English (EN) (415.03 KB - PDF)

**First published:** 27/02/2024

[View](/en/documents/assessment-report/naveruclif-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Naveruclif

Adopted

Reference Number: EMA/CHMP/481586/2023

English (EN) (106.44 KB - PDF)

**First published:** 10/11/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-naveruclif_en.pdf)

#### News on Naveruclif

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023) 10/11/2023

**This page was last updated on** 12/08/2025

## Share this page

[Back to top](#main-content)